ArticleFrontiers in medicine2026
Visual performance and patient-reported outcomes of a non-apodized diffractive trifocal intraocular lens in Chinese cataract patients: a prospective multicenter real-world study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess clinical visual performance and patient-reported satisfaction following bilateral implantation of a non-apodized diffractive trifocal intraocular lens (IOL), the AcrySof Methods: This was a prospective, multicenter registry study including patients aged ≥ 18 years with bilateral age-related or complicated cataracts who underwent bilateral implantation of the PanOptix IOL. The primary endpoint was the proportion of patients achieving binocular uncorrected distance (UDVA), intermediate (UIVA), and near (UNVA) visual acuity of ≤0.200 logMAR at 3 months postoperatively. Secondary endpoints included best-corrected distance visual acuity (BCDVA), binocular defocus curves ranging from +2.00 D to -4.00 D, refractive predictability, and patient-reported outcomes assessed using the Catquest-9SF and IOLSAT questionnaires. The study was registered at Chinese Clinical Trial Registry (ChiCTR2100052791; 2021-11-05). Results: A total of 137 patients completed the 3-months postoperative follow-up. At 3 months, the mean binocular UDVA, UIVA, and UNVA were 0.017 ± 0.086, 0.061 ± 0.110, and 0.061 ± 0.103 logMAR, respectively. Overall, 91.24% of patients achieved the composite endpoint of ≤0.200 logMAR binocularly at all three distances. The binocular defocus curve demonstrated a broad plateau of visual acuity, maintaining ≤0.200 logMAR between +0.50 D and -2.50 D. Refractive predictability was high, with 84.62% of eyes within ±0.50 D of emmetropia. Complete spectacle independence was reported by 96.90% of patients. Conclusion: Bilateral implantation of the PanOptix trifocal IOL provides excellent and early stable visual performance at distance, intermediate, and near in Chinese cataract patients. High refractive predictability and a high rate of spectacle independence are associated with substantial patient satisfaction in real-world clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.